REGN up +1.61% percent Today $REGN High is at 407.96 and the Low 399.18 with current volume of 195,187.
Recent News posted below.
Regeneron Pharmaceuticals REGN other info.
http://investorshangout.com/Regeneron-Pharmac...EGN-55275/
REGN Regeneron Pharmaceuticals Recent Headline News
Eylea expands label in Japan
Seeking Alpha - at Seeking Alpha - 1 hr 6 mins ago
SNY: 48.20 (+0.66), REGN: 407.57 (+7.92)
Cramer's Mad Money - Globalstar Defends Itself (11/17/14)
SA Editor Miriam Metzinger - Seeking Alpha - Tue Nov 18, 5:37AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday November 17. CEO Interview Jay Monroe, Globalstar (NYSEMKT: GSAT ) Jay Monroe, CEO of Globalstar ( GSAT ) appeared on Mad Money to defend the company...
CST: 42.77 (+0.86), WHR: 177.66 (+2.11), MPC: 93.01 (+0.50), HAL: 49.84 (+0.61), TSN: 42.76 (-0.27), SHW: 240.57 (+1.26), GSAT: 2.68 (-0.12), REGN: 407.57 (+7.92), LULU: 45.39 (+0.97), BHI: 66.00 (+0.77)
Jim Cramer's Top Stock Picks: REGN CST MPC LULU
at The Street - Tue Nov 18, 5:00AM CST
Lululemon is worth a second look now and CST Brands would be a perfect fit for a refiner like Marathon Petroleum.
CST: 42.77 (+0.86), MPC: 93.01 (+0.50), REGN: 407.57 (+7.92), LULU: 45.39 (+0.97)
Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Diabetic Macular Edema (DME) in Japan
PR Newswire - Tue Nov 18, 2:05AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for EYLEA® (aflibercept) Injection for diabetic macular edema (DME).
REGN: 407.57 (+7.92)
Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 42.77 (+0.86), BIIB: 305.44 (+3.02), GE: 26.84 (+0.23), NKE: 95.90 (-0.16), HAL: 49.83 (+0.60), TSN: 42.76 (-0.27), GSAT: 2.68 (-0.12), LULU: 45.39 (+0.97), AGN: 211.75 (+2.55), MACK: 8.92 (+0.30), WHR: 177.66 (+2.11), UA: 69.26 (+0.37), DSX: 7.87 (+0.05), ALNY: 91.35 (+2.37), MPC: 93.01 (+0.50), JCP: 7.30 (+0.04), SHW: 240.57 (+1.26), MBLY: 47.40 (+0.42), REGN: 407.57 (+7.92), BHI: 66.00 (+0.77)
SmarTrend Watching for Potential Pullback in Shares of Regeneron Pharmaceuticals After 1.13% Gain
Comtex SmarTrend(R) - Mon Nov 17, 4:43PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $395.20 to a high of $408.29. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $402.87 on volume of 885,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 407.57 (+7.92)
Regeneron Pharmaceuticals Earnings Hindsight: Up 6.1% in Last 13 Days (REGN)
Comtex SmarTrend(R) - Mon Nov 17, 1:39PM CST
13 days ago, on November 4th, 2014, Regeneron Pharmaceuticals (NASDAQ:REGN) reported its earnings. Analysts, on average, expected earnings of $2.57 per share on sales of $733.3 million. The company actually reported EPS of $2.52 on sales of $725.8 million, missing EPS estimates by $0.05 and missing revenue estimates by $7.5 million. Shares of Regeneron Pharmaceuticals have climbed from $372.39 to $395.20, representing a gain of 6.1% since the company reported earnings 13 days ago.
REGN: 407.57 (+7.92)
Merck Drug Works: Vytorin Study Proves Successful
at Investor's Business Daily - Mon Nov 17, 12:35PM CST
Merck (MRK) cholesterol drug Vytorin, an ezetimibe-simvastatin combo, successfully cuts the risk of heart attacks and strokes in high-risk patients more than simvastatin alone, said the drugmaker in its nearly decade-long, 18,144-patient study. "In...
PFE: 30.38 (+0.06), MRK: 59.59 (+0.13), AMGN: 159.86 (+0.72), REGN: 407.57 (+7.92)
Why Novartis and Regeneron Care About This Tiny Biotech Stock
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 14, 2:00PM CST
Source: Flickr user Ali T It may seem a bit odd to think that drug giants Novartis and Regeneron are paying attention to the far smaller Ophthotech Corp . After all, big companies like these tend to acquire small companies or...
OPHT: 40.40 (+0.25), REGN: 407.57 (+7.92), NVS: 95.39 (+1.01)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 305.44 (+3.02), VRTX: 110.80 (-0.82), GILD: 102.18 (+1.74), ALXN: 189.51 (+2.73), AMGN: 159.86 (+0.72), IBB: 293.65 (+4.81), REGN: 407.57 (+7.92), CELG: 105.75 (+1.39)
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Alexander J. Poulos - Seeking Alpha - Fri Nov 14, 8:23AM CST
It is not often for one to come across such an explosive growth company such as Gilead Sciences (NASDAQ: GILD ). By virtue of its stronghold on the Hepatitis C market (HCV) combined with its dominant share in the HIV market, GILD has many...
GILD: 102.18 (+1.74), AMGN: 159.86 (+0.72), SNY: 48.20 (+0.66), REGN: 407.57 (+7.92)
Meet 5 U.S. Techs, Biotechs With Strong Fundamentals
at Investor's Business Daily - Thu Nov 13, 7:02AM CST
With the market in confirmed uptrend and stock indices approaching new highs, focusing on companies with the best fundamentals, such as Regeneron Pharmaceuticals, is a ticket to winners that are likely to outperform the market. Today's Screen Of The...
JPM: 60.60 (+0.22), LNKD: 223.61 (+0.33), SFY: 6.07 (+0.03), CYBR: 42.85 (-0.60), FB: 74.51 (+0.27), ALXN: 189.51 (+2.73), TGT: 66.52 (-0.61), DATA: 83.51 (+0.20), TWTR: 41.06 (+0.59), PANW: 109.97 (+0.62), REGN: 407.57 (+7.92)
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 211.77 (+2.57), ABBV: 65.34 (+0.30), SNY: 48.20 (+0.66), REGN: 407.57 (+7.92)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 110.48 (-1.14), GILD: 102.17 (+1.73), ACHN: 13.54 (+0.22), DNDN: 0.15 (unch), AMGN: 159.86 (+0.72), ABBV: 65.32 (+0.28), REGN: 407.57 (+7.92)
Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Nov 12, 4:20AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday November 11. CEO Interview: Bill Tauscher, Blackhawk (NASDAQ: HAWK ). Other stocks mentioned: Safeway (NYSE: SWY ) Blackhawk ( HAWK ) is a leading global...
WFM: 47.87 (+0.46), DHI: 24.60 (+0.11), AMZN: 328.06 (+5.01), TSLA: 258.32 (+4.34), KR: 58.42 (+0.13), SWY: 34.84 (+0.09), CLX: 100.21 (-0.81), XOM: 95.36 (+0.25), FCAU: 12.71 (+0.18), INO: 10.26 (+0.33), WHR: 177.66 (+2.11), T: 35.72 (-0.13), ISIS: 50.32 (+1.31), VALE: 8.60 (-0.25), EOG: 96.70 (+0.35), HAWK: 36.39 (+0.48), SHW: 240.57 (+1.26), VZ: 51.15 (-0.25), TOL: 33.98 (+0.14), REGN: 407.57 (+7.92), KELYA: 15.48 (+0.40), BABA: 110.75 (-3.50)
Jim Cramer's 'Mad Money' Recap: Pile Into Housing, Biotech and Pop Cult Names
at The Street - Tue Nov 11, 7:59PM CST
Cramer says record-low interest rates seem to have finally paid off for the home builders. That means good things for the folks who make interior items, too.
DHI: 24.60 (+0.11), TSLA: 258.32 (+4.34), AMZN: 328.06 (+5.01), CY: 10.20 (+0.17), XOM: 95.36 (+0.25), KEX: 101.67 (-1.33), LRN: 12.77 (+0.04), BWLD: 161.31 (+1.52), ADBE: 70.74 (+0.77), GTLS: 43.96 (+0.73), TWX: 79.99 (-0.41), WHR: 177.66 (+2.11), T: 35.72 (-0.13), LYB: 88.60 (+0.90), ISIS: 50.32 (+1.31), CMG: 660.52 (+2.20), EOG: 96.70 (+0.35), HAWK: 36.39 (+0.48), SHW: 240.57 (+1.26), VZ: 51.15 (-0.25), DOW: 51.33 (+0.21), REGN: 407.57 (+7.92), KELYA: 15.48 (+0.40), CBS: 52.48 (-0.40)
Asthma treatment passes trial
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) jointly announced positive results from a phase 2 study of dupilumab in patients with moderate to severe uncontrolled asthma, who often struggle with daily symptoms and recurring asthma attacks. Based...
SNY: 48.20 (+0.66), REGN: 407.57 (+7.92)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 383.49 (+2.35), YHOO: 51.65 (-0.72), AMZN: 328.06 (+5.01), BIIB: 305.44 (+3.02), VRTX: 110.48 (-1.14), FEYE: 31.93 (-0.39), LNKD: 223.59 (+0.31), EBAY: 54.90 (+0.07), GILD: 102.17 (+1.73), AMGN: 159.86 (+0.72), ABBV: 65.32 (+0.28), REGN: 407.57 (+7.92), CELG: 105.75 (+1.39)
Today's Momo Momentum Stock To Watch: Regeneron Pharmaceuticals (REGN)
at The Street - Tue Nov 11, 8:51AM CST
Trade-Ideas LLC identified Regeneron Pharmaceuticals (REGN) as a momo momentum candidate
REGN: 407.57 (+7.92)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.59 (+0.13), AZN: 73.35 (+0.85), AMGN: 159.86 (+0.72), TEVA: 57.50 (+0.26), THRX: 13.70 (+0.40), GSK: 46.15 (+0.27), SNY: 48.20 (+0.66), REGN: 407.57 (+7.92), NVS: 95.39 (+1.01)
Recent News posted below.
Regeneron Pharmaceuticals REGN other info.
http://investorshangout.com/Regeneron-Pharmac...EGN-55275/
REGN Regeneron Pharmaceuticals Recent Headline News
Eylea expands label in Japan
Seeking Alpha - at Seeking Alpha - 1 hr 6 mins ago
SNY: 48.20 (+0.66), REGN: 407.57 (+7.92)
Cramer's Mad Money - Globalstar Defends Itself (11/17/14)
SA Editor Miriam Metzinger - Seeking Alpha - Tue Nov 18, 5:37AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday November 17. CEO Interview Jay Monroe, Globalstar (NYSEMKT: GSAT ) Jay Monroe, CEO of Globalstar ( GSAT ) appeared on Mad Money to defend the company...
CST: 42.77 (+0.86), WHR: 177.66 (+2.11), MPC: 93.01 (+0.50), HAL: 49.84 (+0.61), TSN: 42.76 (-0.27), SHW: 240.57 (+1.26), GSAT: 2.68 (-0.12), REGN: 407.57 (+7.92), LULU: 45.39 (+0.97), BHI: 66.00 (+0.77)
Jim Cramer's Top Stock Picks: REGN CST MPC LULU
at The Street - Tue Nov 18, 5:00AM CST
Lululemon is worth a second look now and CST Brands would be a perfect fit for a refiner like Marathon Petroleum.
CST: 42.77 (+0.86), MPC: 93.01 (+0.50), REGN: 407.57 (+7.92), LULU: 45.39 (+0.97)
Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Diabetic Macular Edema (DME) in Japan
PR Newswire - Tue Nov 18, 2:05AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for EYLEA® (aflibercept) Injection for diabetic macular edema (DME).
REGN: 407.57 (+7.92)
Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 42.77 (+0.86), BIIB: 305.44 (+3.02), GE: 26.84 (+0.23), NKE: 95.90 (-0.16), HAL: 49.83 (+0.60), TSN: 42.76 (-0.27), GSAT: 2.68 (-0.12), LULU: 45.39 (+0.97), AGN: 211.75 (+2.55), MACK: 8.92 (+0.30), WHR: 177.66 (+2.11), UA: 69.26 (+0.37), DSX: 7.87 (+0.05), ALNY: 91.35 (+2.37), MPC: 93.01 (+0.50), JCP: 7.30 (+0.04), SHW: 240.57 (+1.26), MBLY: 47.40 (+0.42), REGN: 407.57 (+7.92), BHI: 66.00 (+0.77)
SmarTrend Watching for Potential Pullback in Shares of Regeneron Pharmaceuticals After 1.13% Gain
Comtex SmarTrend(R) - Mon Nov 17, 4:43PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $395.20 to a high of $408.29. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $402.87 on volume of 885,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 407.57 (+7.92)
Regeneron Pharmaceuticals Earnings Hindsight: Up 6.1% in Last 13 Days (REGN)
Comtex SmarTrend(R) - Mon Nov 17, 1:39PM CST
13 days ago, on November 4th, 2014, Regeneron Pharmaceuticals (NASDAQ:REGN) reported its earnings. Analysts, on average, expected earnings of $2.57 per share on sales of $733.3 million. The company actually reported EPS of $2.52 on sales of $725.8 million, missing EPS estimates by $0.05 and missing revenue estimates by $7.5 million. Shares of Regeneron Pharmaceuticals have climbed from $372.39 to $395.20, representing a gain of 6.1% since the company reported earnings 13 days ago.
REGN: 407.57 (+7.92)
Merck Drug Works: Vytorin Study Proves Successful
at Investor's Business Daily - Mon Nov 17, 12:35PM CST
Merck (MRK) cholesterol drug Vytorin, an ezetimibe-simvastatin combo, successfully cuts the risk of heart attacks and strokes in high-risk patients more than simvastatin alone, said the drugmaker in its nearly decade-long, 18,144-patient study. "In...
PFE: 30.38 (+0.06), MRK: 59.59 (+0.13), AMGN: 159.86 (+0.72), REGN: 407.57 (+7.92)
Why Novartis and Regeneron Care About This Tiny Biotech Stock
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 14, 2:00PM CST
Source: Flickr user Ali T It may seem a bit odd to think that drug giants Novartis and Regeneron are paying attention to the far smaller Ophthotech Corp . After all, big companies like these tend to acquire small companies or...
OPHT: 40.40 (+0.25), REGN: 407.57 (+7.92), NVS: 95.39 (+1.01)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 305.44 (+3.02), VRTX: 110.80 (-0.82), GILD: 102.18 (+1.74), ALXN: 189.51 (+2.73), AMGN: 159.86 (+0.72), IBB: 293.65 (+4.81), REGN: 407.57 (+7.92), CELG: 105.75 (+1.39)
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Alexander J. Poulos - Seeking Alpha - Fri Nov 14, 8:23AM CST
It is not often for one to come across such an explosive growth company such as Gilead Sciences (NASDAQ: GILD ). By virtue of its stronghold on the Hepatitis C market (HCV) combined with its dominant share in the HIV market, GILD has many...
GILD: 102.18 (+1.74), AMGN: 159.86 (+0.72), SNY: 48.20 (+0.66), REGN: 407.57 (+7.92)
Meet 5 U.S. Techs, Biotechs With Strong Fundamentals
at Investor's Business Daily - Thu Nov 13, 7:02AM CST
With the market in confirmed uptrend and stock indices approaching new highs, focusing on companies with the best fundamentals, such as Regeneron Pharmaceuticals, is a ticket to winners that are likely to outperform the market. Today's Screen Of The...
JPM: 60.60 (+0.22), LNKD: 223.61 (+0.33), SFY: 6.07 (+0.03), CYBR: 42.85 (-0.60), FB: 74.51 (+0.27), ALXN: 189.51 (+2.73), TGT: 66.52 (-0.61), DATA: 83.51 (+0.20), TWTR: 41.06 (+0.59), PANW: 109.97 (+0.62), REGN: 407.57 (+7.92)
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 211.77 (+2.57), ABBV: 65.34 (+0.30), SNY: 48.20 (+0.66), REGN: 407.57 (+7.92)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 110.48 (-1.14), GILD: 102.17 (+1.73), ACHN: 13.54 (+0.22), DNDN: 0.15 (unch), AMGN: 159.86 (+0.72), ABBV: 65.32 (+0.28), REGN: 407.57 (+7.92)
Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Nov 12, 4:20AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday November 11. CEO Interview: Bill Tauscher, Blackhawk (NASDAQ: HAWK ). Other stocks mentioned: Safeway (NYSE: SWY ) Blackhawk ( HAWK ) is a leading global...
WFM: 47.87 (+0.46), DHI: 24.60 (+0.11), AMZN: 328.06 (+5.01), TSLA: 258.32 (+4.34), KR: 58.42 (+0.13), SWY: 34.84 (+0.09), CLX: 100.21 (-0.81), XOM: 95.36 (+0.25), FCAU: 12.71 (+0.18), INO: 10.26 (+0.33), WHR: 177.66 (+2.11), T: 35.72 (-0.13), ISIS: 50.32 (+1.31), VALE: 8.60 (-0.25), EOG: 96.70 (+0.35), HAWK: 36.39 (+0.48), SHW: 240.57 (+1.26), VZ: 51.15 (-0.25), TOL: 33.98 (+0.14), REGN: 407.57 (+7.92), KELYA: 15.48 (+0.40), BABA: 110.75 (-3.50)
Jim Cramer's 'Mad Money' Recap: Pile Into Housing, Biotech and Pop Cult Names
at The Street - Tue Nov 11, 7:59PM CST
Cramer says record-low interest rates seem to have finally paid off for the home builders. That means good things for the folks who make interior items, too.
DHI: 24.60 (+0.11), TSLA: 258.32 (+4.34), AMZN: 328.06 (+5.01), CY: 10.20 (+0.17), XOM: 95.36 (+0.25), KEX: 101.67 (-1.33), LRN: 12.77 (+0.04), BWLD: 161.31 (+1.52), ADBE: 70.74 (+0.77), GTLS: 43.96 (+0.73), TWX: 79.99 (-0.41), WHR: 177.66 (+2.11), T: 35.72 (-0.13), LYB: 88.60 (+0.90), ISIS: 50.32 (+1.31), CMG: 660.52 (+2.20), EOG: 96.70 (+0.35), HAWK: 36.39 (+0.48), SHW: 240.57 (+1.26), VZ: 51.15 (-0.25), DOW: 51.33 (+0.21), REGN: 407.57 (+7.92), KELYA: 15.48 (+0.40), CBS: 52.48 (-0.40)
Asthma treatment passes trial
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) jointly announced positive results from a phase 2 study of dupilumab in patients with moderate to severe uncontrolled asthma, who often struggle with daily symptoms and recurring asthma attacks. Based...
SNY: 48.20 (+0.66), REGN: 407.57 (+7.92)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 383.49 (+2.35), YHOO: 51.65 (-0.72), AMZN: 328.06 (+5.01), BIIB: 305.44 (+3.02), VRTX: 110.48 (-1.14), FEYE: 31.93 (-0.39), LNKD: 223.59 (+0.31), EBAY: 54.90 (+0.07), GILD: 102.17 (+1.73), AMGN: 159.86 (+0.72), ABBV: 65.32 (+0.28), REGN: 407.57 (+7.92), CELG: 105.75 (+1.39)
Today's Momo Momentum Stock To Watch: Regeneron Pharmaceuticals (REGN)
at The Street - Tue Nov 11, 8:51AM CST
Trade-Ideas LLC identified Regeneron Pharmaceuticals (REGN) as a momo momentum candidate
REGN: 407.57 (+7.92)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.59 (+0.13), AZN: 73.35 (+0.85), AMGN: 159.86 (+0.72), TEVA: 57.50 (+0.26), THRX: 13.70 (+0.40), GSK: 46.15 (+0.27), SNY: 48.20 (+0.66), REGN: 407.57 (+7.92), NVS: 95.39 (+1.01)
